6 citations
,
February 2023 in “Advances in Therapy” Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
September 2023 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil may be effective for hair loss treatment.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Psoriasis patients experience moderate functional impairment related to disease severity and less satisfaction.
50 citations
,
September 2009 in “Molecular Genetics and Metabolism” A new gene mutation causes vitamin D resistance and rickets, treatable with calcium therapy.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
August 2024 in “Frontiers in Public Health” Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.
2 citations
,
November 2024 in “PLoS ONE” Genomic prediction can improve breeding strategies for Korean Sapsaree dogs.
67 citations
,
August 2004 in “Endocrinology” A specific gene mutation causes vitamin D resistance, but certain vitamin D analogs might help.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
2 citations
,
October 2023 in “Frontiers in Immunology” People with rheumatoid arthritis have a higher risk of developing alopecia areata.
January 2023 in “Figshare” Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
6 citations
,
November 2017 in “Scientific reports” The R343H mutation in the VDR gene causes vitamin D-resistant rickets with alopecia by impairing specific gene activity.
The Breast Utility Instrument was developed to assess quality of life in breast cancer patients.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
November 2022 in “The Caucasus” The document's conclusion cannot be provided because the content is not in a readable format.
32 citations
,
August 1984 in “Lancet” July 2024 in “Journal of Investigative Dermatology” Allergies, especially both seasonal and food, increase the risk of developing alopecia areata.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
October 2023 in “Psychiatry research. Case reports” A new HRAS gene variant may cause a range of symptoms including intellectual disability and psychiatric issues.
1 citations
,
December 2022 in “Clinical, cosmetic and investigational dermatology” Arab hair is generally thicker but less dense compared to other ethnicities, affecting hair disorder diagnosis and treatment.
6 citations
,
November 2021 in “Oncology Research and Treatment” Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
March 2023 in “JAAD case reports”
Baricitinib helps regrow hair in teens with severe alopecia areata.
3 citations
,
April 2015 in “AFRICAN JOURNAL OF BIOTECHNOLOGY” Certain genetic markers on the Y-chromosome may influence prostate cancer risk in Iraqi males.
March 2023 in “Editora e-Publicar eBooks”
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.